CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma

Robert B Rebhun, Michael S Kent, S. A E B Borrofka, S. Frazier, Katherine A Skorupski, C. O. Rodriguez

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalVeterinary and Comparative Oncology
Volume9
Issue number1
DOIs
StatePublished - Mar 2011

Fingerprint

T-Cell Lymphoma
lymphoma
drug therapy
Canidae
T-lymphocytes
Dogs
Drug Therapy
dogs
Therapeutics
vincristine
prednisone
hypercalcemia
doxorubicin
cyclophosphamide
Hypercalcemia
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival

Keywords

  • Canine
  • Chemotherapy
  • CHOP
  • Lymphoma
  • T cell

ASJC Scopus subject areas

  • veterinary(all)

Cite this

CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma. / Rebhun, Robert B; Kent, Michael S; Borrofka, S. A E B; Frazier, S.; Skorupski, Katherine A; Rodriguez, C. O.

In: Veterinary and Comparative Oncology, Vol. 9, No. 1, 03.2011, p. 38-44.

Research output: Contribution to journalArticle

@article{8fc09c52c9c5412fbe07cde4200816c9,
title = "CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma",
abstract = "Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).",
keywords = "Canine, Chemotherapy, CHOP, Lymphoma, T cell",
author = "Rebhun, {Robert B} and Kent, {Michael S} and Borrofka, {S. A E B} and S. Frazier and Skorupski, {Katherine A} and Rodriguez, {C. O.}",
year = "2011",
month = "3",
doi = "10.1111/j.1476-5829.2010.00230.x",
language = "English (US)",
volume = "9",
pages = "38--44",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma

AU - Rebhun, Robert B

AU - Kent, Michael S

AU - Borrofka, S. A E B

AU - Frazier, S.

AU - Skorupski, Katherine A

AU - Rodriguez, C. O.

PY - 2011/3

Y1 - 2011/3

N2 - Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).

AB - Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P = 0.01).

KW - Canine

KW - Chemotherapy

KW - CHOP

KW - Lymphoma

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=79551700698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551700698&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5829.2010.00230.x

DO - 10.1111/j.1476-5829.2010.00230.x

M3 - Article

C2 - 21303452

AN - SCOPUS:79551700698

VL - 9

SP - 38

EP - 44

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 1

ER -